Yuanquan Yang

The Ohio State University Comprehensive Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Summary of treatment de-escalation. Overview of dose de-escalation, number ( n ) of patients at each level, and number of patients experiencing a DLT at each dose level. bid, twice daily; D, day; IV, intravenously; PO, orally; qd, once a day.

Year:

2025

Elimusertib concentrations by toxicity. DLT occurrence and week 1 cumulative elimusertib based on day 2 AUC 0–12 hours by cisplatin dose. Open circles, individual patients; solid dash, geometric mean.

Year:

2025

Purpose: The ataxia telangiectasia and Rad3–related kinase inhibitor elimusertib synergizes with cisplatin preclinically. We evaluated the clinical feasibility of combining elimusertib with cisplatin. Patients and Methods: Patients with advanced solid tumors who had received 2 of prior cisplatin, and for whom cisplatin-based treatment was deemed appropriate, were enrolled according to a standard 3 + 3 design, starting elimusertib at 20 mg orally twice daily on days 2 and 9, with cisplatin 60 mg/m 2 intravenously on day 1 of a 21-day cycle. Primary objectives were the determination of the maximum tolerated dose and safety. Secondary objectives included the assessment of elimusertib pharmacokinetics and preliminary efficacy. Results: Fifteen patients were enrolled. Dose level −2 (elimusertib 20 mg once on day 2 and cisplatin 30 mg/m 2 on days 1 and 8) was deemed the maximum tolerated dose; dose-limiting toxicities (DLT) including creatinine increase, hypokalemia, febrile neutropenia, neutropenia, syncope, and thrombocytopenia, required dose de-escalation. Although the four patients with the highest elimusertib exposure all experienced hematologic DLTs within 1 week, they also received a higher day 1 cisplatin dose, precluding a definitive association of elimusertib exposure with DLT occurrence. Of 10 evaluable patients, one (10%) with clear-cell ovarian cancer had a partial response, whereas five (50%) had stable disease. Conclusions: Cisplatin combined with elimusertib was associated with hematologic toxicity requiring significant dose de-escalation. Elimusertib pharmacokinetics was consistent with prior studies. Only modest activity was observed. Further clinical evaluation of elimusertib plus cisplatin is not warranted. Significance: Preclinical data suggest synergy between cisplatin and the ataxia telangiectasia and Rad3–related inhibitor elimusertib, leading to this phase Ib trial in advanced solid tumors evaluating feasibility. The results do not support further examination of the combination due to DLTs observed in the absence of robust efficacy.

Year:

2025

Year:

2023

Collaborators (8)

Paul Frankel

Research Professor

Beckman Research Institute, City of Hope

UNITED STATES
View details

Arjun Mittra

Assistant Professor

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Jan Beumer

Professor (PAR)

Johns Hopkins University

UNITED STATES
View details

Ming Yin

Assistant Professor

The Ohio State University Wexner Medical Center

UNITED STATES
View details

Anne Noonan

Professor

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Philippe L. Bedard

University Health Network

CANADA
View details

Nataliya Uboha

Associate Professor

University of Wisconsin-Madison Carbone Cancer Center

UNITED STATES
View details

Mamta Parikh

Associate Professor

University of California Davis Comprehensive Cancer Center

UNITED STATES
View details